AstraZeneca is advancing understanding of cardio-renal-metabolic interconnectivity with new evidence at ESC 2018

New evidence of the persistency of ischaemic risk in post-heart attack patients, highlighting specific risk factors that may help identify patients for extended DAPT

Latest data on the links between RAAS inhibitor dose reduction and increased risk
of mortality and MACE in heart failure patients with hyperkalaemia

First Phase IIa trial results on MEDI6012 in atherosclerosis,
demonstrating cardio-protective potential

AstraZeneca and MedImmune, its global biologics research and development arm, will present new data from its Cardiovascular, Renal and Metabolism (CVRM) portfolio of medicines at the European Society of Cardiology (ESC) Congress in Munich, Germany, 25-29 August 2018, aiming to help inform clinical practice for the treatment of patients with overlapping CVRM diseases and multiple risk factors.

Highlights will include:

• New real-world evidence on patients most at risk of future cardiovascular events, including death, underlining the need for improved secondary prevention including dual antiplatelet therapy (DAPT). The latest research also aims to inform clinical practice in patients with type-2 diabetes treated with glucose-lowering drugs who may also have coronary artery disease and/or experienced a prior heart attack or stroke
• Evaluation of real-world consequences in sub-optimal renal-angiotensin-aldosterone system (RAAS) inhibitor dosing in the treatment of heart failure patients with hyperkalaemia, aiming to ensure patients receive optimum cardio-renal protection
• Phase IIa results from the first collaboration between MedImmune and TIMI Study Group indicate the potential therapeutic benefit of MEDI6012, a lecithin-cholesterol acyltransferase (LCAT), for the treatment of atherosclerosis in patients having experienced the most serious type of heart attack

Ludovic Helfgott, Vice President, Cardiovascular, Renal and Metabolism at AstraZeneca, said: “At ESC, we continue to explore the intricacies of cardio-renal and metabolic risk with our determination to improve patient outcomes. The data to be presented in Munich this year underscores the persistent ischaemic risk in patients with additional risk factors such as diabetes or multi-vessel disease, and demonstrates clinical benefits in heart failure for patients with hyperkalaemia.”

Increased and persistent ischaemic risk in patients with additional risk factors

• PRECLUDE-2 is an analysis of >100,000 heart attack (myocardial infarction) patients treated with percutaneous coronary intervention (PCI) from the SWEDEHEART registry, examining the additive effects of risk factors (diabetes, renal impairment, age≥65yrs, multi-vessel disease, further heart attacks) on the risk of subsequent ischaemic events and major bleeding events. [Presentation: #1398. Sunday 26 August, 11:18 – 11:35 CEST at Spotlight Village]
• TIGRIS is a global prospective registry study to evaluate clinical management, quality of life and outcomes during a two-year follow-up in high-risk patients with stable coronary artery disease (CAD), one to three years post-myocardial infarction (MI). [Presentation: #5261. Tuesday 28 August, 11:52 – 12:05 CEST at Spotlight Village]
• ATHENA is a Swedish nationwide registry study designed to compare cardiovascular risk in type-2 diabetes patients with any of: a prior MI or stroke; CAD but without prior MI or stroke; or without CAD, prior MI or stroke. [Presentation: #P6425. Sunday 26 August, 14:00 – 18:00 CEST at Poster Area]

Maintaining treatment benefit in heart failure patients with hyperkalaemia

• Results from two real-world studies assessing the impact of RAAS inhibition in heart failure patients with hyperkalaemia:
  • Investigating RAAS inhibitor dosing in heart failure patients including the association between hyperkalaemia and down-titration/discontinuation of RAAS inhibitor therapies. [Presentation: #P1810. Sunday 26 August, 8:30 – 12:30 CEST at Poster Area]
  • The association between RAAS inhibitor dosing and the risk of mortality and major adverse cardiovascular events (MACE) in heart failure patients. [Presentation: #P5671. Tuesday 28 August, 8:30 – 12:30 CEST at Poster Area]

Advancing the cardiology pipeline

• Phase IIa results from a trial investigating MEDI6012 recombinant LCAT in patients with stable atherosclerosis to assess safety and efficacy; this represents the first findings from a new collaboration between MedImmune and the TIMI Study Group. [Presentation: #354. Saturday 25 August, 13:30 – 15:00 CEST at Agora1]

Details of further key abstracts from AstraZeneca/MedImmune: (all times are CEST)

NOTES TO EDITORS

About AstraZeneca in Cardiovascular, Renal & Metabolism (CVRM)

Cardiovascular, renal and metabolic diseases together form one of AstraZeneca’s main therapy areas and platforms for future growth. By following the science to understand more clearly the underlying links between the heart, kidney and pancreas, AstraZeneca is investing in a portfolio of medicines to protect organs and improve outcomes by slowing disease progression, reducing risks and tackling co-morbidities. Our ambition is to modify or halt the natural course of CVRM diseases and even regenerate organs and restore function, by continuing to deliver transformative science that improves treatment practices and cardiovascular health for millions of patients worldwide.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. 

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

CONTACTS